https://neurenpharma.com/activity-updates/y5p23P-jon-pilcher-on-ausbiz-neuren-eyes-global-growth-as-daybue-sales-impress 2025-11-06T23:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/Pb3Dny-jon-pilcher-on-ausbiz 2025-10-19T23:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/rDonGe-biotech-showcase-2025-presentation 2025-09-19T00:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/eN0VKP-jon-pilcher-on-ausbiz-neuren-boosted-by-favourable-sales-forecast 2026-01-13T21:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/yM12by-neuren-pharmaceuticals-under-the-microscope 2025-06-05T00:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/eN6DNe-belldirect-interview 2025-03-19T02:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/PmRbby-marcus-today-on-the-couch-podcast-with-jon-pilcher 2024-11-13T02:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/P3pnQy-sharecafe-and-finance-news-network-presentation 2025-03-18T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/yORDoP-43rd-j-p-morgan-healthcare-conference-presentation-webcast 2025-01-20T02:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/rvKlYP-sharecafe-small-cap-hidden-gems-presentation 2024-10-16T02:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/y1xO1P-asx-ceo-connect 2024-10-25T02:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/eWp45r-refining-clinician-and-caregiver-reported-outcome-measures-for-evaluating-phelan-mcdermid-syndrome 2025-10-21T21:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/Pl6qae-many-apparent-false-negatives-in-detection-of-mutations-in-gene-associated-with-autism-spectrum-disorders 2025-05-28T23:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/P4g2or-nnz-2591-a-synthetic-igf-1-metabolite-analog-phase-2-clinical-trial-results-for-children-and-adolescents-with-pitt-hopkins-syndrome 2025-03-25T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/e9d90y-safety-efficacy-and-exposure-response-of-nnz-2591-a-synthetic-analog-of-cyclic-glycine-proline-cgp-an-igf-1-metabolite-for-the-treatment-of-phelan-mcdermid-syndrome-in-children-and-adolescents 2025-03-25T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/ex968r-the-evolving-genetic-landscape-of-phelan-mcdermid-syndrome-and-implications-for-diagnostics 2025-03-25T21:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/rLWo0e-improving-outcome-measures-for-trials-in-phelan-mcdermid-syndrome-pms-development-of-pms-specific-clinician-and-caregiver-impression-of-change-measures 2024-11-10T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/yE1d4y-nnz-2591-a-novel-igf-1-related-treatment-for-neurodevelopmental-disorders-demonstrates-efficacy-for-children-and-adolescents-with-phelan-mcdermid-syndrome 2024-11-10T21:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/r6J21r-safety-efficacy-and-exposure-response-of-nnz-2591-a-synthetic-analog-of-cyclic-glycine-proline-cgp-an-igf-1-metabolite-for-the-treatment-of-phelan-mcdermid-syndrome-in-children-and-adolescents 2024-10-13T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/PRK23y-safety-efficacy-pharmacokinetics-and-pharmacodynamics-of-nnz-2591-in-children-and-adolescents-with-pitt-hopkins-syndrome 2025-10-21T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/yVnV5y-development-of-clinician-and-caregiver-reported-outcome-measures-for-evaluating-pitt-hopkins-syndrome 2025-10-21T21:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/PK1W7e-nnz-2591-for-the-treatment-of-angelman-syndrome-results-from-a-phase-2-open-label-study 2025-10-21T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/epKO6y-jon-pilcher-on-ausbiz-neuren-powers-ahead-with-new-rett-syndrome-treatment-in-us 2026-04-08T00:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/rJ1Zpe-inside-neu-the-asx-pharma-star-with-a-long-runway-for-growth 2025-10-21T23:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/eg0q3r-marcus-today-on-the-couch-with-jon-pilcher-neuren-pharma-ceo-november-2025 2025-11-28T23:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/Pb3NGy-nnz-2591-in-children-and-adolescents-with-phelan-mcdermid-syndrome 2025-12-23T04:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/PBklQy-jon-pilcher-on-ausbiz-neuren-boosted-by-favourable-sales-forecast 2026-02-11T22:00:00Z monthly 0.6 https://neurenpharma.com/activity-updates/yzmVBP-jon-pilcher-on-ausbiz-neuren-boosted-by-favourable-sales-forecast 2026-03-03T22:00:00Z monthly 0.6